In this Issue
- The Psychedelic Blame Game: NYT Report Fuels Controversy Over MDMA Rejection
- Mixed Messages on Psymposia’s Role
- Lykos and MAPS Seize the Opportunity
- Political Pragmatism Sparks Backlash Among Some Supporters
- Psychedelic Drug Developers Reflect on “Lykos-Specific Issues” and the Road Ahead
- FDA “Wanted to Approve” MDMA, Says MindMed Exec
- Trump on Psychedelics; “Nothing” Lies Beyond Psychological Support; Trial Site Availability Limits Psychedelic Drug Development
- GH’s 5-MeO-DMT Data and RFK Jr. Confirmation Send Psychedelics Stocks Soaring
- Other Stories, Including: Beckley Shares Data from Phase 2a 5-MeO-DMT Study • MindMed Doses First Patient in Second Phase 3 Study of LSD in GAD • California Medical Association Adopts Resolution Calling for Reduced Regulatory Burdens on Psilocybin, AMA to Vote in June • UK Refreshes ILAP Program • Case Report Details Suicide of Psilocybin-Assisted Therapy Patient • International Collaboration Between UK, Canadian, and U.S. Psychedelic Industry Groups Announced • Tacoma City Council Makes ‘Entheogen-Related Activities’ Low Law Enforcement Priority • PitchBook 97% Confident Beckley IPOs this Year • PharmAla Signs Advisory Agreement with Matthew Azrieli • Ambio Life Sciences Publishes Case Report on Ibogaine in 2 MS Patients • Compass-Backed Trigger Law Bills Appear in Iowa, Kansas • U.S. Embassy in Peru and Costa Rica Authorities Warn Against Psychedelics • 2025 Florida Farm Bill Clamps Down on Amanita muscaria.
***
The Psychedelic Blame Game: NYT Report Fuels Controversy Over MDMA Rejection
Earlier this week, The New York Times published a story that, above all, suggests that Psymposia was substantially to blame for FDA’s August rejection of Lykos Therapeutics’ MDMA-assisted therapy for PTSD new drug application (NDA), and that “other psychedelic drugs in the pipeline could be jeopardized.” Murmurs of the reporting had been swirling for some time and its publication has been met with excitement by many in the field.
Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…
Join Pα+ Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue
